Buy 60 38.00 20180515-09:17 Buy 2'400 38.00 20180515-09:19 Buy 2'500 38.00 20180515-09:19 Buy 427 38.00 20180515-09:19 Buy 8'073 38.00 20180515-09:19 Buy 347 38.00 20180515-09:19 Buy ...

Allschwil, Switzerland, April 30, 2018   First CXCR4 antagonist to demonstrate proof of concept in solid tumors Combination with eribulin shows very promising anti-tumor activity in heavily pre-treated metastatic breast cancer patient...

Allschwil, Switzerland, April 24, 2018 Murepavadin demonstrates extremely potent activity against extensively drug resistant (XDR) Pseudonomas aeruginosa isolates New OMPTAs display potent bactericidal activity against all gram-negative WH...

Allschwil, Switzerland, April 19, 2018 Polyphor announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its novel immuno-oncology candidate balixafortide (POL6326), in combination with eribulin,...

Allschwil, Switzerland, April 16th, 2018 Polyphor today announced that the company will present data on its Outer Membrane Targeting Antibiotics (OMPTAs) and lead compound murepavadin (POL7080) at the 28th European Congress of Clinical Microbiol...

Allschwil, Switzerland, April 13th, 2018 Final milestone reached ahead of schedule triggering payment of a CHF 0.97M convertible loan amount Polyphor today announced that it has successfully completed its Wellcome Trust collaboration which s...

Allschwil, Switzerland, March 27th, 2018 Polyphor announces enrollment of first patient in Phase III clinical trial for murepavadin - a pathogen-specific antibiotic being developed for the treatment of nosocomial pneumonia Potentially first...

Allschwil, Switzerland, March 23rd, 2018 Polyphor presents positive proof of concept data for innovative immuno-oncology candidate balixafortide at European Breast Cancer Conference Polyphor announced today the presentation of positive data fr...

Allschwil, Switzerland, March 9th, 2018 Possibility of proceeding with a single pivotal trial to file for approval in the U.S. for combination with eribulin as third line therapy for metastatic breast cancer Polyphor announced today the succ...

Allschwil, Switzerland, February 15, 2018 Polyphor to receive CHF6.5 million upfront and is eligible for additional CHF121 million in future milestone payments plus tiered double-digit royalties Polyphor announced today that it has entered i...

Allschwil, Switzerland, January 23, 2018 Polyphor: Global No. 2 in the 2018 Biopharmaceuticals Antimicrobial Resistance Benchmark published by the Access to Medicine Foundation   PolyphorPolyphor has been selected by the Access to Medicine Foun...

Allschwil, Switzerland, October 12, 2017, 09:00 CET Funding up to proof-of-concept in man will be provided for EUR 5 million by Polyphor and for another EUR 5 million by IMI via the funding of a consortium dedicated to the development of...

Allschwil, Switzerland, July 18, 2017, 09:00 CET Polyphor Ltd. announced today that it has made significant progress in the discovery and early development of novel broad-spectrum, outer membrane protein targeting Gram-negative antibiotics (O...

Allschwil, Switzerland, July 10, 2017, 09:00 CET Polyphor contributes to the progress in understanding Neutrophil Elastase Science Polyphor Ltd. in collaboration with academic groups presented on July 7th three posters related to Neutrophil ...

Allschwil, Switzerland, May 24, 2017, 15:00 CET Kalina Scott appointed new CFO of Polyphor Kalina Scott will join Polyphor as Chief Financial Officer as of June 1st, 2017. She brings over 20 years of experience in the fields of mergers &...

Allschwil, Switzerland, May 19, 2017, 09:00CET Polyphor announces successful end of phase II meeting with FDA for Murepavadin in nosocomial pneumonia Allschwil, Switzerland, May 19, 2017 - Polyphor Ltd., a clinical stage, privately held Swis...

Outer-Membrane Protein Targeting Antibiotics (OMPTAs) - New hope against antibiotic resistance - Important step forward for nosocomial pneumonia treatment - Vienna, Austria, April 24, 2017 - Polyphor today presented promising data for their...

Polyphor announces two oral and six poster presentations plus a press conference at the 27th ECCMID Congress, Vienna Allschwil, Switzerland, 20 April, 2017. Polyphor announces today its presence at ECCMID with two oral and six poster present...

Polyphor announces closing of CHF 40 million private financing round Allschwil, Switzerland, April 12, 2017 - Polyphor Ltd., a clinical stage, privately held Swiss specialty pharma company focused on the development of macrocycle drugs addre...

/ Press release Polyphor AG Chief Medical and Development OfficerMarch 06, 2017, 12:00 AM CET Debra Barker Appointed New CMDO of Polyphor Allschwil, Switzerland, March 06, 2...

Polyphor Receives CHF 2.3 Million Award from Wellcome Trust to Accelerate the Development of a Novel Antibiotic Drug Class Allschwil, Switzerland, February 09, 2017 - Polyphor Ltd. announces today that it has received a CHF 2.3 million award ...

Polyphor achieves milestone in Taisho collaboration Allschwil, Switzerland, December 12, 2016. Polyphor Ltd. today announces the achievement of an important milestone in its collaboration with Taisho Pharmaceutical Co., Ltd. ("Taisho"), to ide...

Polyphor achieves milestone and extends R&D collaboration Allschwil, Switzerland, December 07, 2016. Polyphor Ltd, announces today the achievement of a pre-clinical milestone and the extension of its R&D collaboration with Novartis triggering ...

Giacomo Di Nepi Appointed New CEO of Polyphor Allschwil, Switzerland, October 18, 2016. - Polyphor has announced the appointment of Giacomo Di Nepi as the new CEO. He will assume responsibilities on November 1st, 2016. Michael Altorfer will su...

Polyphor and Gilead establish R&D macrocycle drug discovery collaboration Allschwil, Switzerland, August 10, 2016. Polyphor Ltd announced today the signing of a collaboration and license agreement with Gilead Sciences Inc., Foster City, Calif...

The issuer is solely responsible for the content of this announcement. Polyphor successfully completes clinical Phase I study with POL6014 targeting life threatening lung diseases including cystic fibrosis Allschwil, Switzerland, June 06, 201...

The issuer is solely responsible for the content of this announcement. Polyphor announces $3 Million Award from Cystic Fibrosis Foundation Therapeutics to advance the clinical development of POL6014 Allschwil, Switzerland, March 23, 2016. Pol...

The issuer is solely responsible for the content of this announcement. Polyphor and Boehringer Ingelheim extend macrocycle R&D collaboration Allschwil, Switzerland, December 22, 2015. Polyphor Ltd, a privately held pharmaceutical compan...

The issuer is solely responsible for the content of this announcement. Polyphor announces extension of R&D collaboration Allschwil, Switzerland, December 1, 2015. Polyphor Ltd, a privately held pharmaceutical company, announced today t...

Polyphor and Taisho enter into research collaboration on novel drug candidates Allschwil, Switzerland, September 17, 2015. Polyphor Ltd, a privately held pharmaceutical company specialized in the discovery and development of macrocycle drugs,...

Polyphor extends clinical development portfolio by advancing its inhaled elastase inhibitor POL6014 for lung diseases to Phase I Allschwil, Switzerland, September 1, 2015. Polyphor Ltd, a privately held pharmaceutical company specialized in t...